Our study demonstrated that intraprostatic [ 11 C]-choline uptake in the 11 analyzed prostate cancer patients significantly declined during and after ebrt. The pet parameters SUV max and tmr also declined significantly. These effects can be detected during radiation therapy and up to 1 year after therapy. The prognostic value of these early and statistically significant changes in intraprostatic 
INTRODUCTION

[ 11 C]-Choline Positron-Emission Tomography in Prostate Cancer
Positron-emission tomography (pet) has proved to be useful as a noninvasive imaging tool suitable for the diagnosis and staging of prostate cancer 1 . Use of the most common pet radiotracer, [ 18 F]-fluoro-2-deoxyd-glucose ([ 18 F]-fdg), has led to mixed results based on its overlapping accumulation in normal prostate tissue, benign prostatic hyperplasia, and prostate cancer tissue [2] [3] [4] . Furthermore, accumulation of [ 18 F]-fdg in the urinary bladder may mask uptake in the prostate gland and pelvic nodes, limiting their assessment 5 . False-positive results were reported for prostatitis 6 based on the accumulation of [ 18 F]-fdg in inflamed prostate glands. Assessment of androgen
ABSTRACT
Purpose
The objective of the present study was to analyze, with relatively high sensitivity and specificity, uptake properties of [ 11 C]-choline in prostate cancer patients by means of positron-emission tomography (pet)/ computed tomography (ct) imaging using objectively defined pet parameters to test for statistically significant changes before, during, and after external-beam radiation therapy (ebrt) and to identify the time points at which the changes occur.
Methods
The study enrolled 11 patients with intermediate-risk prostate cancer treated with ebrt, who were followed for up to 12 months after ebrt. The [ 11 C]-choline pet scans were performed before treatment (baseline); at weeks 4 and 8 of ebrt; and at 1, 2, 3, 6, and 12 months after ebrt.
Results
Analysis of [ 11 C]-choline uptake in prostate tissue before treatment resulted in a maximum standardized uptake value (suv max ) of 4.0 ± 0.4 (n = 11) at 40 minutes after injection. During week 8 of ebrt, the suv max declined to 2.9 ± 0.1 (n = 10, p < 0.05). At 2 and 12 months after ebrt, suv max values were 2.3 ± 0.3 (n = 10, p < 0.01) and 2.2 ± 0.2 (n = 11, p < 0.001) respectively, indicating that, after ebrt, maximum radiotracer uptake in the prostate was significantly reduced. Similar effects were observed when analyzing the tumour:muscle ratio (tmr). The tmr declined from 7.4 ± 0.6 (n = 11) before ebrt to 6.1 ± 0.4 (n = 11, nonsignificant) during week 8 of ebrt, to 5.6 ± 0.03 (n = 11, p < 0.05) at 2 months after ebrt, and to 4.4 ± 0.4 (n = 11, p < 0.001) at 12 months after ebrt. 16, 17 . Uptake of [ 11 C]-choline correlates with increased levels of prostate-specific antigen (psa) in some studies, but that finding is not consistent in the literature 1 . Observations during androgen deprivation therapy with bicalutamide or leuprolide provided evidence for the usefulness of [ 11 C]-choline pet when monitoring therapy in prostate cancer patients 18, 19 . A preclinical study analyzing therapy response to docetaxel has shown that [ 11 C]-choline pet may be a valuable tool for monitoring response to taxane-based chemotherapy in patients with advanced prostate cancer 20 .
[ 11 C]-Choline PET to Objectively Evaluate Early
Response to External-Beam Radiation Therapy Specific molecular imaging approaches for prostate carcinoma may provide valuable information for the design and implementation of adaptive radiation therapy techniques and early assessment of the efficacy of novel radiation therapy approaches (such as hypofractionated radiation therapy), potentially serving as valuable surrogate endpoints 21 . Assessment of the local control rate in prostate carcinoma has so far been accomplished by posttreatment core biopsies; however, the accuracy of this method is limited by sampling error and posttreatment changes 22 . Functional imaging modalities such as magnetic resonance imaging (mri) and pet have provided evidence for improved assessment and evaluation of local control and the response of prostate cancer to treatment 23, 24 . Although the role of pet as a monitoring standard for the therapy of prostate cancer remains to be clarified, the use of pet radiotracers in therapy planning is an area of active and growing research 25 . Promising data suggest a potential clinical role for [ 11 C]-choline pet as an imaging tool in the irradiation treatment of prostate cancer relapse 26 . When step-section histologic analysis of prostatectomy specimens was compared with preoperative intraprostatic imaging, [ 11 C]-choline pet was shown to be more sensitive and specific than mri in detecting primary prostate lesions 27, 28 .
The goal of the present prospective study was to evaluate the feasibility of using [ 11 C]-choline pet/ct with relatively high sensitivity and specificity, with objectively defined pet parameters, to test for statistically significant changes before, during, and after external-beam radiation therapy (ebrt) and to identify the time points at which the changes occur.
METHODS
Our Institutional Research Ethics Committee approved this clinical study. All patients enrolled gave written informed consent.
Patient Population
This prospective study enrolled 11 patients (50-79 years of age) with intermediate-risk localized prostate cancer. "Intermediate risk" was defined by applying the widely used D'Amico criteria: Gleason score 7, psa less than 20 ng/mL, and T1-T2C; or Gleason score 6, psa 10-20 ng/mL, and T1-T2C; or Gleason score 6 or 7, psa less than 20 ng/mL, and T2C 29 . All patients underwent staging at diagnosis, including determination of baseline psa level, a digital rectal exam, bone scan using [ 99m Tc]-methylene diphosphonate, and ct imaging of abdomen and pelvis.
Radiation Treatment
All 11 patients received ebrt using intensity-modulated radiation therapy to a dose of at least 74 Gy, at 2 Gy per fraction daily, for a period of 8 weeks. None of the patients received hormonal therapy.
PET Imaging
The [ 11 C]-choline was synthesized at the Edmonton PET Centre according to a "loop" synthesis method using [ 11 C]-iodomethane 30 . For all patients, [ 11 C]-choline pet measurements were performed on a pet/ct scanner (Gemini GS: Philips Healthcare, Best, Netherlands) dynamically in 2-minute time increments from injection to 40 minutes after injection. Patients fasted for 12 hours before each pet study and received approximately 400 MBq [ 11 C]-choline intravenously for each scan. Radiotracer injection occurred immediately after the start of the pet, which in turn commenced after acquisition of the ct images. The [ 11 C]-choline pet images were obtained before treatment (baseline), at weeks 4 and 8 of ebrt, and at 1, 2, 3, 6, and 12 months after ebrt.
Image Data Analysis
The pet data were reconstructed using the 3-dimensional row action maximum likelihood algorithm (2 iterations) with standard clinical settings, including all corrections (randoms, scatter, attenuation, decay). The reconstructed images were analyzed using the Region of Interest Visualization, Evaluation and Image Registration software (ABX Advanced Biochemical Compounds, Radeberg, Germany). Prostate uptake was quantified by placing a spherical region ("mask") on the prostate and querying the voxel with maximum suv (suv max ) within the mask. Tracer uptake in muscle was quantified by placing a spherical mask on muscular tissue of uniform uptake in the upper thigh; the mean suv (suv mean ) within that region was then calculated and recorded. The tumour-to-muscle ratio (tmr) was calculated as the ratio of the prostate suv max to the muscle suv mean . The suv max and tmr values were both determined at baseline and at each follow-on scan up to 60 weeks. At each time point, the suvs and tmrs for all patients, and the standard error of the mean calculated for each of those two parameters, were averaged. The statistical analysis of suv max and tmr at each time point relative to baseline was performed using the Student t-test. Values of p < 0.05 were considered statistically significant. Figure 1 (A) depicts the patient-averaged suv max of the prostate at 40 minutes after injection for the 8 [ 11 C]-choline pet studies from baseline to 60 weeks. Images obtained before treatment resulted in a suv max of 4.0 ± 0.4 (n = 11). At week 8 of ebrt, the suv max declined to 2.9 ± 0.1 (n = 11, p < 0.05). At 2 months after ebrt, the suv max further declined to 2.3 ± 0.3 (n = 10, p < 0.01). Up to 12 months after ebrt, the suv max remained low [measuring 2.2 ± 0.2 (n = 11, p < 0.001)], indicating that, compared with baseline, the maximum radiotracer uptake was significantly reduced after ebrt.
RESULTS
SUV max Before and After EBRT
TMR Before and After EBRT
The tmrs were calculated from the suv max of the tumour lesion and the subsequent suv mean of muscle tissue. Figure 1(B) shows the observed changes in tmr values over time. At the 8th week of ebrt, tmr had declined to 6.1 ± 0.4 (n = 11, nonsignificant). At 2 months after ebrt, the tmr had declined further to 5.6 ± 0.3 (n = 11, p < 0.05). The tmr remained low up to 12 months after ebrt, measuring 4.4 ± 0.4 (n = 11, p < 0.001).
Table i summarizes the suv max and tmr values for each individual study patient at week 0 (baseline scan), week 8 (8th week of ebrt), week 16 (2 months after ebrt), and week 60 (1 year after ebrt). Both parameters were reduced during and after radiation therapy and remained approximately constant (suv max ) or declined even further (tmr) at the 1-year follow-up [ 11 C]-choline pet.
Correlation with PSA
Prostate-specific antigen was determined before ebrt (week 0), and at 16, 20, 32, and 60 weeks. Levels of psa declined from a pre-treatment 13.6 ± 1.5 ng/mL (n = 11) to 2.1 ± 0.5 ng/mL (n = 10) at 16 weeks and further to 2.1 ± 0.5 ng/mL (n = 6) at 1 year after radiation therapy [ Figure 2 
DISCUSSION
In recent years, the use of noninvasive pet/ct imaging for the detection of primary prostate cancer has increased in many centres worldwide, especially using those trends, no final recommendations for the use of pet/ct in the diagnosis, staging, and treatment of prostate cancer have been published by either the American Urological Association or the European Association of Urology. Also, the use of [ 11 C]-and [ 18 F]-choline for monitoring and planning prostate cancer radiotherapy has yet to be elucidated 25, 26 .
The results of the present study suggest that [ 11 C]-choline pet may be used to detect early posttreatment changes in patients with intermediate-risk prostate cancer during and after ebrt. A [ 11 C]-choline pet was able to detect statistically significant intraprostatic changes during and up to 1 year after ebrt. The baseline suv max (4.0) observed in our study is consistent with similar results by Reske et al. 14 , who used [ 11 C]-choline pet to determine a baseline suv max of 3.5 ± 1.3 (mean ± standard deviation) based on a diagnostic study of 26 prostate cancer patients. The authors indicated a mean psa of 14.4 ng/mL, which is similar in range to the mean psa (13.6 ng/mL) in the present study. In comparison, Giovacchini et al. 18 reported a higher baseline suv max of 5.4 ± 1.7 (mean ± standard deviation), with a mean psa of 12.9 ng/mL for patients not undergoing neoadjuvant androgen deprivation therapy. Based on the analysis by Reske et al. 14 , suv max values of 2.0, 1.7, and 2.1 were associated with benign prostatic hyperplasia, normal prostate tissue, and focal prostatitis respectively, and a suv max of 2.5 was considered the optimal threshold to distinguish between benign and malignant histopathology. A suv max of 2.2 and a psa of 2.1 ng/mL at 1 year after ebrt in the present study is below the estimated threshold for malignant histopathology; however, the threshold needs to be confirmed with biopsies for histology and long-term follow-up of biochemical disease-free survival and local recurrence rates in this patient population. Clinical local recurrence rates for intermediate-risk prostate cancer treated with dose-escalated ebrt are generally low, and therefore the low-average post-ebrt suv max in our study is consistent with this finding. Positive correlation between [ 11 C]-choline suv max and psa level is controversial 1 ; no such correlation was found in the data from the patient population in the present study, neither at baseline, nor at 60 weeks. On the other hand, the lower suv max after 1 year does correlate with the lower psa determined at the same time. In a recent study using Comparisons between imaging modalities have shown that [ 11 C]-choline and [ 18 F]-choline carry high sensitivity and specificity for diagnostic molecular imaging of primary intraprostatic lesions 27, 28 or the detection of locally recurrent or metastatic disease 1 . There is still a paucity of data in the published literature about the quantitative evaluation of functional changes in the prostate after ebrt and the time interval over which those changes might occur. Local recurrences of prostate cancer are difficult to detect with transrectal ultrasound. Other imaging modalities-for example, mri-have been proved to be more sensitive than transrectal ultrasound, but they have significant detection limits 24 . However, pet using a variety of radiotracers has shown higher accuracy for the detection of residual and recurrent prostate cancer. Patients with psa values below 1 ng/mL are unlikely to have detectable local recurrence by either mri or pet after therapy, but a possible threshold psa value of more than 2 ng/ mL has been demonstrated for detection of local recurrence after radiation therapy with the use of [ The present study was designed to evaluate [ 11 C]-choline intraprostatic uptake during and after ebrt with the aim of determining how soon functional changes occur. It demonstrated that a decrease in suv max and tmr was detectable during ebrt and that, before the end of radiation therapy, the changes reached statistical significance. Long-term observation (up to 1 year after therapy) saw a further decrease in suv max and tmr. Longer follow-up to correlate the early changes in objective imaging parameters with biochemical disease-free survival is indicated and may provide avenues for early salvage treatment of specific patients after ebrt if these statistically significant and early [ 11 C]-choline pet changes are found to demonstrate response.
CONCLUSIONS
The present study demonstrated that intraprostatic [ 11 C]-choline uptake in prostate cancer (which has relatively high sensitivity and specificity) is significantly reduced during ebrt according to the objectively defined pet parameters suv max and tmr, and that it remains reduced for up to 1 year after ebrt. The current data support the use of [ 11 C]-choline pet for the detection of early functional changes in intraprostatic tumour tissue during and after ebrt. The prognostic implications of these statistically significant early functional intraprostatic changes are not established. It is important to note that the findings in the present study are not sufficient to show that [ 11 C]-choline is a biomarker of response. Future studies are indicated to correlate changes in specific [ 11 C]-choline uptake parameters with long-term biochemical recurrence. Further evaluation of [ 11 C]-choline response is warranted as a possible (but currently unproven) method to risk-stratify patients for early salvage treatment based on pet response after ebrt.
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